NASDAQ:REPL

Replimune Group Competitors

$30.23
-0.86 (-2.77 %)
(As of 04/16/2021 11:01 AM ET)
Add
Compare
Today's Range
$29.75
Now: $30.23
$30.91
50-Day Range
$29.35
MA: $32.87
$36.30
52-Week Range
$10.62
Now: $30.23
$54.85
Volume2,942 shs
Average Volume382,265 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.63

Competitors

Replimune Group (NASDAQ:REPL) Vs. VIR, CBPO, ALLO, BEAM, IOVA, and SWTX

Should you be buying REPL stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Replimune Group, including Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), and SpringWorks Therapeutics (SWTX).

Replimune Group (NASDAQ:REPL) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Replimune Group and Vir Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Replimune Group00903.00
Vir Biotechnology20502.43

Replimune Group currently has a consensus target price of $56.00, suggesting a potential upside of 85.25%. Vir Biotechnology has a consensus target price of $66.00, suggesting a potential upside of 43.73%. Given Replimune Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Replimune Group is more favorable than Vir Biotechnology.

Valuation & Earnings

This table compares Replimune Group and Vir Biotechnology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A$-52,630,000.00($1.54)-19.63
Vir Biotechnology$8.09 million726.46$-174,680,000.00($5.76)-7.97

Replimune Group has higher earnings, but lower revenue than Vir Biotechnology. Replimune Group is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Replimune Group and Vir Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Replimune GroupN/A-30.23%-24.66%
Vir Biotechnology-339.61%-47.11%-39.44%

Risk & Volatility

Replimune Group has a beta of 2.63, suggesting that its share price is 163% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500.

Insider and Institutional Ownership

55.8% of Replimune Group shares are held by institutional investors. Comparatively, 54.5% of Vir Biotechnology shares are held by institutional investors. 50.9% of Replimune Group shares are held by insiders. Comparatively, 37.2% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Replimune Group beats Vir Biotechnology on 12 of the 13 factors compared between the two stocks.

Replimune Group (NASDAQ:REPL) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

55.8% of Replimune Group shares are held by institutional investors. Comparatively, 34.8% of China Biologic Products shares are held by institutional investors. 50.9% of Replimune Group shares are held by insiders. Comparatively, 2.7% of China Biologic Products shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Replimune Group has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares Replimune Group and China Biologic Products' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A$-52,630,000.00($1.54)-19.63
China Biologic Products$503.70 million9.24$138.81 million$4.2827.63

China Biologic Products has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Replimune Group and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Replimune GroupN/A-30.23%-24.66%
China Biologic Products27.43%8.32%7.64%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Replimune Group and China Biologic Products, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Replimune Group00903.00
China Biologic Products0000N/A

Replimune Group presently has a consensus price target of $56.00, suggesting a potential upside of 85.25%. Given Replimune Group's higher possible upside, analysts plainly believe Replimune Group is more favorable than China Biologic Products.

Summary

China Biologic Products beats Replimune Group on 7 of the 12 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Allogene Therapeutics and Replimune Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
Replimune GroupN/A-30.23%-24.66%

Valuation & Earnings

This table compares Allogene Therapeutics and Replimune Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.73
Replimune GroupN/AN/A$-52,630,000.00($1.54)-19.63

Replimune Group is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

59.9% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 55.8% of Replimune Group shares are owned by institutional investors. 31.3% of Allogene Therapeutics shares are owned by insiders. Comparatively, 50.9% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Allogene Therapeutics and Replimune Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
Replimune Group00903.00

Allogene Therapeutics currently has a consensus price target of $52.0833, indicating a potential upside of 60.55%. Replimune Group has a consensus price target of $56.00, indicating a potential upside of 85.25%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts clearly believe Replimune Group is more favorable than Allogene Therapeutics.

Volatility & Risk

Allogene Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500.

Summary

Replimune Group beats Allogene Therapeutics on 7 of the 11 factors compared between the two stocks.

Beam Therapeutics (NASDAQ:BEAM) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Beam Therapeutics and Replimune Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam Therapeutics-529,075.00%-103.41%-48.05%
Replimune GroupN/A-30.23%-24.66%

Earnings and Valuation

This table compares Beam Therapeutics and Replimune Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.00228,577.73$-78,330,000.00($14.05)-5.21
Replimune GroupN/AN/A$-52,630,000.00($1.54)-19.63

Replimune Group has lower revenue, but higher earnings than Beam Therapeutics. Replimune Group is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 55.8% of Replimune Group shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by company insiders. Comparatively, 50.9% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Beam Therapeutics and Replimune Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics03302.50
Replimune Group00903.00

Beam Therapeutics currently has a consensus target price of $96.00, indicating a potential upside of 31.18%. Replimune Group has a consensus target price of $56.00, indicating a potential upside of 85.25%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts clearly believe Replimune Group is more favorable than Beam Therapeutics.

Summary

Replimune Group beats Beam Therapeutics on 10 of the 12 factors compared between the two stocks.

Replimune Group (NASDAQ:REPL) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Replimune Group and Iovance Biotherapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Replimune Group00903.00
Iovance Biotherapeutics011002.91

Replimune Group currently has a consensus target price of $56.00, indicating a potential upside of 85.25%. Iovance Biotherapeutics has a consensus target price of $50.50, indicating a potential upside of 64.87%. Given Replimune Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Replimune Group is more favorable than Iovance Biotherapeutics.

Profitability

This table compares Replimune Group and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Replimune GroupN/A-30.23%-24.66%
Iovance BiotherapeuticsN/A-50.64%-45.64%

Volatility and Risk

Replimune Group has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

55.8% of Replimune Group shares are owned by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Replimune Group and Iovance Biotherapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A$-52,630,000.00($1.54)-19.63
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-18.96

Replimune Group is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Replimune Group beats Iovance Biotherapeutics on 8 of the 11 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations for SpringWorks Therapeutics and Replimune Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00403.00
Replimune Group00903.00

SpringWorks Therapeutics currently has a consensus target price of $95.20, suggesting a potential upside of 33.26%. Replimune Group has a consensus target price of $56.00, suggesting a potential upside of 85.25%. Given Replimune Group's higher possible upside, analysts clearly believe Replimune Group is more favorable than SpringWorks Therapeutics.

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500.

Earnings and Valuation

This table compares SpringWorks Therapeutics and Replimune Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.12
Replimune GroupN/AN/A$-52,630,000.00($1.54)-19.63

SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SpringWorks Therapeutics and Replimune Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Replimune GroupN/A-30.23%-24.66%

Insider & Institutional Ownership

76.3% of SpringWorks Therapeutics shares are held by institutional investors. Comparatively, 55.8% of Replimune Group shares are held by institutional investors. 51.2% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 50.9% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Replimune Group beats SpringWorks Therapeutics on 6 of the 10 factors compared between the two stocks.


Replimune Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$45.92-1.9%$5.76 billion$8.09 million-19.46Analyst Downgrade
Insider Selling
News Coverage
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26-0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.44-1.3%$4.62 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.18-0.8%$4.61 billion$20,000.00-5.21
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.14-1.0%$4.43 billionN/A-15.70Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$71.44-3.0%$3.60 billionN/A-41.06Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.01-1.6%$3.25 billion$125.57 million-42.70Insider Selling
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.39-4.1%$3.05 billionN/A0.00News Coverage
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32-3.1%$2.96 billion$50.04 million0.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$35.35-15.9%$2.76 billion$20.53 million-20.32Analyst Report
Gap Up
Vericel logo
VCEL
Vericel
1.1$58.62-1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.36-1.1%$2.09 billion$31.43 million-5.04Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.94-2.7%$2.00 billion$44.67 million-2.64
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.85-0.8%$1.95 billionN/A-11.14Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.50-0.2%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$76.36-0.3%$1.70 billionN/A-51.59
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Immunovant logo
IMVT
Immunovant
1.8$15.42-3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51-3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
AlloVir logo
ALVR
AlloVir
1.4$22.08-2.4%$1.44 billionN/A0.00Increase in Short Interest
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.08-2.6%$1.42 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.55-6.7%$1.34 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.78-0.4%$1.06 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.41-5.9%$1.00 billionN/A0.00Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.00-6.8%$979.79 million$42.74 million-222.22Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$16.16-6.4%$925.89 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.01-0.8%$911.40 millionN/A-4.13Insider Selling
Increase in Short Interest
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.68-1.4%$840.75 million$69.89 million-4.22
Cellectis logo
CLLS
Cellectis
1.3$19.13-0.9%$825.65 million$22.99 million-10.18
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$18.03-16.4%$680.60 millionN/A0.00Decrease in Short Interest
Gap Up
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$19.90-1.8%$656.65 million$5.78 million-9.34Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.35-1.5%$630.05 million$9.86 million-9.07
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.12-8.9%$628.01 millionN/A0.00Lockup Expiration
Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.